On April 7, 2014, Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) announced multiple presentations on ITI-007 at the 4th Biennial Schizophrenia International Research Society (SIRS) Conference. Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) shares after opening at $16.64 moved to $18.61 on last trade day and at the end of the day closed at $18.36. Company price to sales ratio in past twelve months was calculated as 195.80. Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) showed a negative weekly performance of -3.37%.
Zogenix Inc. (NASDAQ:ZGNX) the company that manufactures the recently approved Zohydro ER, a single-entity extended-release (ER) hydrocodone, has filed a lawsuit in the US District Court in Massachusetts, requesting a temporary restraining order against execution of an executive order by that state’s governor banning prescription and dispensing of its product. Zogenix, Inc. (NASDAQ:ZGNX) shares advanced 8.49% in last trading session and ended the day on $2.81. ZGNX return on assets is -142.60%. Zogenix, Inc. (NASDAQ:ZGNX) yearly performance is 70.30%.
On March 27, 2014, the Compensation Committee of the Board of Directors of Auspex Pharmaceuticals, Inc. (NASDAQ:ASPX) approved discretionary cash bonuses for certain of the Company’s named executive officers and the Company’s principal financial officer. Auspex Pharmaceuticals, Inc. (NASDAQ:ASPX) shares moved up 2.45% in last trading session and was closed at $3.14, while trading in range of $3.08 – $3.16. Auspex Pharmaceuticals, Inc. (NASDAQ:ASPX) year to date (YTD) performance is -10.03%.
Rockwell Medical (NASDAQ:RMTI) on 24 march Submits New Drug Application for Triferic (TM) for the Treatment of Iron Replacement in Chronic Kidney Disease Patients on Hemodialysis. Rockwell Medical Inc. (NASDAQ:RMTI) weekly performance is -7.97%. On last trading day company shares ended up $11.78. Rockwell Medical Inc. (NASDAQ:RMTI) distance from 50-day simple moving average (SMA50) is -3.45%. Analysts mean target price for the company is $17.00.
Leave a Reply